ERBB2 and breast carcinoma: In advanced HER2-positive breast cancer, recent data from the KATE2 trial showed that adding atezolizumab to trastuzumab emtansine (T-DM1) extended progression-free survival (PFS) to 8.2 months compared to 6.8 months for T-DM1 alone, suggesting that immune modulation may benefit specific patient subsets (41)​.